Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: Synthesis, activity, and oral bioavailability

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 2060-2067

  Lehr, Philipp ^a   Billich, Andreas ^a   Charpiot, Brigitte ^a   Ettmayer, Peter ^a   Scholz, Dieter ^a   Rosenwirth, Brigitte ^a   Gstach, Hubert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[(BENZYLOXYCARBONYL) TERT LEUCYL]AMINO] 3 HYDROXY 2 [(4 METHOXYBENZYL)AMINO] 5 PHENYLPENTANOIC ACID 1 AMINO 2 HYDROXYINDANAMIDE; 4 [[(BENZYLOXYCARBONYL)VALYL]AMINO] 3 HYDROXY 2 [(4 METHOXYBENZYL)AMINO] 5 PHENYLPENTANOYLVALINE 2 (AMINOMETHYL)BENZIMIDAZOLAMIDE; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEINASE INHIBITION; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; PENTANOIC ACIDS;

EID: 0029944321     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9508696     Document Type: Article

References (31)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Devis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, W. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. Delfraissy, J. F.; Sereni, D.; Brun-Vezinet, F.; Dussaix, E.; Krivine, A.; Dormont, J.; Bragman, K. A Phase I-II Dose Ranging Study of the Safety and Activity of Ro 31-8959 (HIV Proteinase Inhibitor) in Previously Zidovudine (ZDV) treated HIV-infected Individuals. Poster presented at the 9th International Conference on AIDS, Berlin, 1994; Abstr. WS-B26-3.
3. Kitchen, V.; Skinner, C.; Sedwick, A.; Bragman, K.; Pinching, A. J.; Weber, J. A Phase I-II Dose Ranging Study of the Safety and Activity of Ro 31-8959 (HIV Proteinase Inhibitor) in Asymptomatic or Mildly Symptomatic HIV-infection. Poster presented at the 9th International Conference on AIDS, Berlin, 1994; Abstr. PO-B26-2033.
4. Teppler, H. et al. Pharmacokinetics and Tolerability Studies of L-735,524, a New HIV Protease Inhibitor. First National Conference on Human Retroviruses, 1993; Abstr. L8:152.
5. Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharm. 1994, 25, 399-454.
6. Robins, T.; Plattner, J. HIV Protease Inhibitors: Their Anti-HIV Activity and Potential Role in Treatment. J. Aquired Immune Def. Syndr. 1993, 6, 162-170.
7. Greenlee, W. J. Renin Inhibitors. Med. Res. Rev. 1990, 10, 173-236.
8. Scholz, D.; Billich, A.; Charpiot, B.; Ettmayer, P.; Lehr, P.; Rosenwirth, B.; Schreiner, E.; Gstach, H. Inhibitors of HIV-1 Proteinase containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral Activity. J. Med. Chem. 1994, 37, 3079-3089.
9. Billich, A.; Charpiot, B.; Fricker, G.; Gstach, H.; Lehr, P.; Peichl, P.; Scholz, D.; Rosenwirth, B. HIV Proteinase Inhibitors containing 2-Aminobenzylstatine as a Novel Scissile Bond Replacement: Biochemical and Pharmacological Characterization. Antiviral Res. 1994, 25, 215-233.
10. Lyle, T. A.; Wiscount, C. M.; Guare, J. P.; Thompson, W. J.; Anderson, P. S.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Dixon, R. A. F.; Sigal, I. S.; Huff, J. R. Benzocycloalkyl Amines as Novel C-Termini for HIV Protease Inhibitors. J. Med. Chem. 1991, 34, 1228-1230.
11. Thompson, W. J.; Fitzgerald, P. M.; Holloway, M. K.; Emini, E. A.; Darke, P. L.; McKeever, B. M.; Schleif, W. A.; Quintero, J. C.; Zugay, J. A.; Tucker, T. J.; Schwering, J. E.; Homnick, C. F.; Nunberg, J.; Springer, J. P.; Huff, J. R. Synthesis and Antiviral Activity of a Series of HIV-1 Protease Inhibitors with Functionality Tethered to the P1 or P1′ Phenyl Substituents: X-Ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701.
12. Jacques J.; Collet A.; Wilen, S. H. Enantiomers, Racemates and Resolutions; John Wiley & Sons: New York, 1981.
13. Mikitenko, E. K.; Romanov, N. N. Conversion of Derivatives of 3-Amino-thiazolidine-2-thion-4-one into Substituted Mercapto-1,3,4-thiadiazoles. Dopov. Akad. Nauk. Ukr. RSR, Ser B: Geol., Khim. Biol. Nauki 1980, 10, 56-59.
14. The nomenclature used for describing the individual amino acid residues (P3, P2, P1, P1′, P2′, etc.) of a substrate and the corrresponding subsites (S3, S2, S1, S1′, S2′, etc.) of a protease is that of Schechter and Berger: Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
15. Krömer, R. T.; Ettmayer, P.; Hecht, P. 3D-QSAR of HIV-1 Proteinase Inhibitors: Comparative Molecular Field Analysis of 2-Heterosubstituted Statine Derivatives - Implications for the Design of Novel Inhibitors. J. Med. Chem. 1995, 38, 4917.
16. Appelt, K. Crystal Structures of HIV-1 Protease - Inhibitor Complexes. Perspect. Drug Discovery Des. 1993, 1, 23-48.
17. Tucker, T. J.; Lumma, W. C.; Payne, L. S.; Wai, J. M.; deSolms, S. J.; Giulliani, E. A.; Darke, P. L.; Heimbach, J. C.; Zugay, J. A.; Schleif, W. A.; Quintero, J. C.; Emini, E. A.; Huff, J. R.; Anderson, P. S. A Series of Potent HIV-1 Protease Inhibitors Containing a Hydroxyethyl Secondary Amine Transition State Isostere: Synthesis, Enzyme Inhibition, and Antiviral Activity. J. Med. Chem. 1992, 35, 2525-2533.
18. Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomaselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protese from Human Immunodeficiency Virus; Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952.
19. Young, S. D.; Payne, L. S.; Thompson, W. J.; Gaffin, N.; Lyle, T. A.; Britcher, S. F.; Graham, S. L.; Schultz, T. H.; Deana, A. A.; Darke, P. L.; Zugay, J.; Schleif, W. A.; Quintero, J. C.; Emini, E. A.; Anderson, P. S.; Huff, J. R. HIV-1 Protease Inhibitors Based on Hydroxyethylene Dipeptide Isosteres: an Investigation into the Role of the P1′ Side Chain on Structure-Activity. J. Med. Chem. 1992, 35, 1702-1709.
20. Schirlin, D.; Van Dorsselaer, V.; Tarnus, C.; Taylor, D. L.; Tyms, A. S.; Baltzer, S.; Weber, F.; Remy, J. M.; Farr, R.; Janowick, D. Beneficial Replacement of the P1 Phenylalanine Side Chain in HIV-1 Protease Inhibitors of the Difluorostatone Type. Bioorg. Med. Chem. Lett. 1994, 4, 241-246.
21. Billich, A.; Fricker, G.; Müller, I.; Donatsch, P.; Ettmayer, P.; Gstach, H.; Lehr, P.; Peichl, P.; Scholz, D.; Rosenwirth, B. SDZ PRI-053, an Orally Bioavailable Human Immunodefiency Virus Type 1 Proteinase Inhibitor containing the 2-Aminobenzylstatine Moiety. Antimicrob. Agents Chemother. 1995, 39, 1406-1413.
22. Billich, A.; Winkler, G. Analysis of Subsite Preferences of HIV-1 Proteinase using MA/CA Junction Peptides Substituted at the P3-P1′ Positions. Arch. Biochem. Biophys. 1991, 290, 186-190.
23. Rich, D.; Prasad, J. V. N.; Pathiasseril, Sun, C. Q.; Green, J.; Mueller, R. A.; Houseman, K.; MacKenzie, D.; Malkovsky, M. New Hydroxylethylamine HIV Protease Inhibitors That Suppress Viral Replication. J. Med. Chem. 1992, 35, 3803-3812.
24. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Kröhn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational Design of Peptide-Based HIV Proteinase Inhibitors. Science 1990, 248, 358-361.
25. Billich, A.; Scholz, D.; Charpiot, B.; Gstach, H.; Lehr, P.; Peichl, P.; Rosenwirth, B. Potent and Orally Bioavailable HIV-1 Proteinase Inhibitors containing the 2-Aminobenzylstatine Moiety. Antiviral Chem. Chemother. 1995, 6, 327-336.
26. Seelmeier, S.; Schmidt, H.; Turk, V.; von der Helm, K. Human Immunodeficiency Virus has an Aspartic-type Protease that can be Inhibited by Pepstatin A. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6612-6616.
27. Billich, A.; Hammerschmid, F.; Winkler, G. Purification, Assay and Kinetic Features of HIV-1 Proteinase. Biol. Chem. Hoppe-Seyler 1990, 371, 265-272.
28. Richards, A.; Phylip, L. H.; Farmerie, W. G.; Scarborough, P. E.; Alvarez, A.; Dunn, B. M.; Hirel, P. H.; Konvalinka, J.; Strop, P.; Pavlickova, L.; Kostka, V.; Kay, J. Sensitive, Soluble Chromogenic Substrates for HIV-1 Proteinase. J. Biol. Chem. 1990, 265, 7733-7736.
29. Cha, S.; Agarwal, R. P.; Parks, R. E. Tight-binding Inhibitors. Biochem. Pharmacol. 1975, 24, 2187-2197.
30. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clerq, E. Rapid and Automated Tetrazolium-based Colorimetric Assay for the Detection of anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
31. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection, Isolation, and Continous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.